The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis
Abstract Background Poly (ADP- ribose) polymerase inhibitors (PARPi) has been increasingly adopted for metastatic castration-resistance prostate cancer (mCRPC) patients with homologous recombination repair deficiency (HRD). However, it is unclear which PARPi is optimal in mCRPC patients with HRD in...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2024-06-01
|
| Col·lecció: | BMC Cancer |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12885-024-12388-2 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|